Bradley Merrill Thompson Quoted in “FDA Touts Lessons from Pre-Cert, Though Next Steps Murky”

MedTech Dive

Bradley Merrill Thompson, Member of the Firm in the Health Care & Life Sciences practice, in the firm’s Washington, DC, office, was quoted in MedTech Dive, in  “FDA Touts Lessons from Pre-Cert, Though Next Steps Murky,” by Greg Slabodkin.

Following is an excerpt:

FDA on Monday provided a 2020 update on its yet-to-be finalized software precertification program as well as “learnings” from an ongoing pilot launched in 2019, which includes Apple, Fitbit, Johnson & Johnson and six other companies. …

The Pre-Cert pilot, which entered a formal testing phase last year, is focused on software as a medical device (SaMD), which the agency notes ranges from diagnostic software that allows a smartphone to view MRIs, to computer-aided detection software that performs image post-processing to help detect breast cancer.

While FDA is still working to test and build the yet-to-be finalized program, the agency faces major regulatory hurdles as it will need to go back to Congress to ask for the legislative authority to proceed. At this point, however, FDA has not determined what specific regulations and authorities it would need to make Pre-Cert a reality.

Bradley Merrill Thompson, attorney at Washington, D.C. law firm Epstein Becker Green, said the agency is “investing huge” amounts of time in developing the program, and argues that’s problematic given the lack of statutory authority and the fact that lawmakers might not approve what ultimately emerges.

“Why fully develop a program without any authority, just in the hope that Congress might authorize not just precertification generally, but FDA’s specific approach to precertification? It could be a huge waste of time,” Thompson said.

Nonetheless, without providing a specific timeline in its update on Monday, FDA said it will continue to assess and evaluate the readiness of the Pre-Cert program before advancing to the next phases of development and “will consider obtaining legislative authority” to fully implement it as a new regulatory pathway for SaMD.

While FDA is considering what statutory changes might be needed for regulating SaMD as a result of the evolving Pre-Cert program, the AI Startups in Health Coalitionon Monday released a position paper calling for a “more modest” regulatory approach to reform that they say could occur more swiftly and without the need to change the underlying statutes.

“We favor the agency aggressively moving forward with its AI/ML framework discussions, instead of investing more time on the precertification program,” wrote the startup group, where Thompson serves as general counsel. The group contends the Pre-Cert program is “enormously complex” and will require significant revision to make sure startups are “not disadvantaged vis-à-vis established firms, among other problems with the current proposal.”

“Honestly, that AI/ML framework has a whole lot more excitement behind it with an awful lot of folks in industry, especially startups involved in AI,” Thompson said, urging FDA to “realign its priorities.”